Nasdaq
$1.29▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $58.1MShares out 45.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.16Pre-market26.10.16 20:00RWOther#●●●
RenovoRx, Inc.
RenovoRx has formally requested that the SEC withdraw its Registration Statement on Form S-3 (File No. 333-291547), which was initially filed on November 14, 2025. The registration statement was never declared effective, and no securities were sold in connection with the contemplated offering.…more
$1.29+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 06:004Ownership
RenovoRx, Inc.
Insider Angela K. Macfarlane of RenovoRx, Inc. reported a change in beneficial ownership of securities as of October 1, 2026. This filing serves as a standard Form 4 disclosure regarding insider holdings.…more
$1.29+0.00%vs prev closeView filingShare - 10.2After-hours26.10.03 06:004Ownership
RenovoRx, Inc.
Insider Robert J. Spiegel of RenovoRx, Inc. reported a change in beneficial ownership of securities effective October 1, 2026. This filing is a Form 4 statement detailing the insider's equity transaction.…more
$1.29+0.00%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 21:45#●●●
RenovoRx to Report Third Quarter 2026 Financial Results on November 5
RenovoRx announced it will release its third quarter 2026 financial results and business highlights after market close on November 5, 2026. Management will host a conference call to discuss commercial execution and the company's outlook for revenue growth.…more
$1.29+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.7Pre-market26.10.07 21:35
●●●●●●●● ●●●●● ●●●●●●
RenovoRx has enrolled the first patient in the university-sponsored PRISM-TAMP clinical trial for pancreatic cancer. The study aims to evaluate the efficacy of the company's RenovoCath drug-delivery device in a neoadjuvant treatment setting.…more
$1.29+0.00%vs prev closeShareBenzinga - 10.7Pre-market26.10.07 21:30
●●●●●●●● ●●●●● ●●●●●●
RenovoRx has officially begun patient enrollment for its investigator-initiated PRISM-TAMP trial, evaluating the TAMP platform for borderline resectable pancreatic cancer. The study aims to assess the safety and efficacy of the platform as a neoadjuvant treatment prior to surgical resection.…more
$1.29+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report